News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL, you can't make this shit up!
Now it's time for good news.
LOL! Still trying to convince others to buy this scam.
This belongs in Bankruptcy Court not on the pink sheets. The balance sheet is a disaster.
No end in sight to this dilution...
And magically he disappeared!
They will fund all those things with their overdrawn bank account and zero sales for last quarter! LOL!
Give us a break.
LOL! Repeating the same BS as the last pump and dumper!
This company's contraption doesn't work like they said it did. It lacks real studies. All their scientists left to start their own competitor company as Craig previously posted. They originally were going to acquire this technology for $28 million, then sued and bought it for $4.5 million which is probably what it was worth and proceeded to destroy all its value by proving they couldn't sell the product, dropping the concussion studies, and suing their competitors and failing. So, how on God's green earth is the valuation supposed to suddenly increase over 10x what they paid for it? I guess they plan to sprinkle fairy dust on it.
It has been a year and they still have not gotten it done, guess why? Nobody will issue a valuation for them because they could get sued. Nobody is going to finance it to go onto NASDAQ. It takes around $10 million to get on. Lastly, the debt holders will be the fist to dump the shares in order to get their money, which they will convert to freely traded shares long before any retail investor can. This is another one of the CEO's scams to keep milking money out of investors.
Another Pump & Dump Scammer shows up! How original!
Piece of shit SCAM!
New Target Price is $0.0001 Par Value
Given the last closing price of $0.0004 conversions will be taking place at a 50% discount which is $0.0002 which will drive down the stock price to that value over time. The exact timing is unknown and depends on the rate of selling on behalf of Trillium Partners. A reverse stock split is also on the horizon because they don't have enough authorized shares to cover even half of the amount that is going to be converted into freely traded stock at near par value.
This company's stock is valued at essentially ZERO due to the amount of debt that the company is holding. I don't believe they can sell all that stock to cover the debt and this is heading to a bankruptcy court. I believe Collier is on the hook for some money based on the documents filed a few years ago. My take is that he clears the debt he is a guarantor to before he throws this into bankruptcy. Their spin-out is not working because 1.) Ira cannot raise money based on a bloated valuation and 2.) Collier proved that the pain management device has no lucrative commercial viability.
They bought these assets for $4.5 million several years ago and since then have only tanked the valuation because they abandoned all the potentially lucrative applications of the technology such as the treatment of brain injury and they proved that their pain management device was not commercially viable. Simply put, acquiring this company at a $75 million valuation would produce a company who's only "asset" would be goodwill created by the bloated acquisition price.
It means a R/S and/or increase in Authorized shares is coming.
This notice is also very late, a month late. Very likely we already had a conversion at $0.00025-$0.0003
BUYER BEWARE: $2.9 Million in debt to be converted at a 50% discount.
ENDV just lost a lawsuit and filed the following today:
On November 14, 2024, in a case entitled Trillium Partners, L.P. (“Trillium”) v Endonovo Therapeutics, Inc. (the “Company”) in the Circuit Court for the 17th Judicial Circuit in and for Broward County Florida (Case No CACE24009960), the court issued an order (the “Order”) approving a settlement of $2,896,956.15 of the Company’s outstanding debt in exchange for the issuance of shares at a 50% discount to market under Section 3(a)(10) of the Securities Act of 1933, as amended. The shares, when issued pursuant to the Order, will be free of any restriction and be marketable securities. As a result of the Order, the Company’s outstanding indebtedness was reduced from approximately $2,896,956.15. The sale of shares under the Order, which has not yet commenced, may have a depressive affect on the market for the Company’s shares.
AI
